Cargando…

Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study

BACKGROUND: A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection dif...

Descripción completa

Detalles Bibliográficos
Autores principales: Auvigne, Vincent, Vaux, Sophie, Strat, Yann Le, Schaeffer, Justine, Fournier, Lucie, Tamandjou, Cynthia, Montagnat, Charline, Coignard, Bruno, Levy-Bruhl, Daniel, Parent du Châtelet, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121907/
https://www.ncbi.nlm.nih.gov/pubmed/35611065
http://dx.doi.org/10.1016/j.eclinm.2022.101455
_version_ 1784711239756152832
author Auvigne, Vincent
Vaux, Sophie
Strat, Yann Le
Schaeffer, Justine
Fournier, Lucie
Tamandjou, Cynthia
Montagnat, Charline
Coignard, Bruno
Levy-Bruhl, Daniel
Parent du Châtelet, Isabelle
author_facet Auvigne, Vincent
Vaux, Sophie
Strat, Yann Le
Schaeffer, Justine
Fournier, Lucie
Tamandjou, Cynthia
Montagnat, Charline
Coignard, Bruno
Levy-Bruhl, Daniel
Parent du Châtelet, Isabelle
author_sort Auvigne, Vincent
collection PubMed
description BACKGROUND: A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omicron versus Delta. METHODS: We conducted a retrospective cohort study to compare severe hospital events (admission to intensive care unit or death) between Omicron and Delta symptomatic cases matched according to week of virological diagnosis and age. The analysis was adjusted for age, sex, vaccination status, presence of comorbidities and region of residence, using Cox proportional hazards model. FINDINGS: Between 06/12/2021–28/01/2022, 184 364 cases were included, of which 931 had a severe hospital event (822 Delta, 109 Omicron). The risk of severe event was lower among Omicron versus Delta cases; the difference in severity between the two variants decreased with age (adjusted Hazard Ratio (aHR)=0·13 95%CI: 0·08–0·20 among 40–64 years, aHR=0·50 95%CI: 0·26–0.98 among 80+ years). The risk of severe event increased with the presence of comorbidities (for very-high-risk comorbidity, aHR=4·15 95%CI: 2·86–6·01 among 40–64 years) and in males (aHR=2·28 95%CI: 1·82–2·85among 40–64 years) and was higher in unvaccinated compared to primo-vaccinated (aHR=7·29 95%CI: 5·58–9·54 among 40–64 years). A booster dose reduced the risk of severe hospital event in 80+ years infected with Omicron (aHR=0·29; 95%CI: 0·12–0·69). INTERPRETATION: This study confirms the lower severity of Omicron compared to Delta. However, the difference in disease severity is less marked in the elderly. Further studies are needed to better understand the interactions between age and severity of variants. FUNDING: The study was performed as part of routine work at Public Health France.
format Online
Article
Text
id pubmed-9121907
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91219072022-05-20 Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study Auvigne, Vincent Vaux, Sophie Strat, Yann Le Schaeffer, Justine Fournier, Lucie Tamandjou, Cynthia Montagnat, Charline Coignard, Bruno Levy-Bruhl, Daniel Parent du Châtelet, Isabelle eClinicalMedicine Articles BACKGROUND: A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omicron versus Delta. METHODS: We conducted a retrospective cohort study to compare severe hospital events (admission to intensive care unit or death) between Omicron and Delta symptomatic cases matched according to week of virological diagnosis and age. The analysis was adjusted for age, sex, vaccination status, presence of comorbidities and region of residence, using Cox proportional hazards model. FINDINGS: Between 06/12/2021–28/01/2022, 184 364 cases were included, of which 931 had a severe hospital event (822 Delta, 109 Omicron). The risk of severe event was lower among Omicron versus Delta cases; the difference in severity between the two variants decreased with age (adjusted Hazard Ratio (aHR)=0·13 95%CI: 0·08–0·20 among 40–64 years, aHR=0·50 95%CI: 0·26–0.98 among 80+ years). The risk of severe event increased with the presence of comorbidities (for very-high-risk comorbidity, aHR=4·15 95%CI: 2·86–6·01 among 40–64 years) and in males (aHR=2·28 95%CI: 1·82–2·85among 40–64 years) and was higher in unvaccinated compared to primo-vaccinated (aHR=7·29 95%CI: 5·58–9·54 among 40–64 years). A booster dose reduced the risk of severe hospital event in 80+ years infected with Omicron (aHR=0·29; 95%CI: 0·12–0·69). INTERPRETATION: This study confirms the lower severity of Omicron compared to Delta. However, the difference in disease severity is less marked in the elderly. Further studies are needed to better understand the interactions between age and severity of variants. FUNDING: The study was performed as part of routine work at Public Health France. Elsevier 2022-05-20 /pmc/articles/PMC9121907/ /pubmed/35611065 http://dx.doi.org/10.1016/j.eclinm.2022.101455 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Auvigne, Vincent
Vaux, Sophie
Strat, Yann Le
Schaeffer, Justine
Fournier, Lucie
Tamandjou, Cynthia
Montagnat, Charline
Coignard, Bruno
Levy-Bruhl, Daniel
Parent du Châtelet, Isabelle
Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study
title Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study
title_full Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study
title_fullStr Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study
title_full_unstemmed Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study
title_short Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study
title_sort severe hospital events following symptomatic infection with sars-cov-2 omicron and delta variants in france, december 2021–january 2022: a retrospective, population-based, matched cohort study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121907/
https://www.ncbi.nlm.nih.gov/pubmed/35611065
http://dx.doi.org/10.1016/j.eclinm.2022.101455
work_keys_str_mv AT auvignevincent severehospitaleventsfollowingsymptomaticinfectionwithsarscov2omicronanddeltavariantsinfrancedecember2021january2022aretrospectivepopulationbasedmatchedcohortstudy
AT vauxsophie severehospitaleventsfollowingsymptomaticinfectionwithsarscov2omicronanddeltavariantsinfrancedecember2021january2022aretrospectivepopulationbasedmatchedcohortstudy
AT stratyannle severehospitaleventsfollowingsymptomaticinfectionwithsarscov2omicronanddeltavariantsinfrancedecember2021january2022aretrospectivepopulationbasedmatchedcohortstudy
AT schaefferjustine severehospitaleventsfollowingsymptomaticinfectionwithsarscov2omicronanddeltavariantsinfrancedecember2021january2022aretrospectivepopulationbasedmatchedcohortstudy
AT fournierlucie severehospitaleventsfollowingsymptomaticinfectionwithsarscov2omicronanddeltavariantsinfrancedecember2021january2022aretrospectivepopulationbasedmatchedcohortstudy
AT tamandjoucynthia severehospitaleventsfollowingsymptomaticinfectionwithsarscov2omicronanddeltavariantsinfrancedecember2021january2022aretrospectivepopulationbasedmatchedcohortstudy
AT montagnatcharline severehospitaleventsfollowingsymptomaticinfectionwithsarscov2omicronanddeltavariantsinfrancedecember2021january2022aretrospectivepopulationbasedmatchedcohortstudy
AT coignardbruno severehospitaleventsfollowingsymptomaticinfectionwithsarscov2omicronanddeltavariantsinfrancedecember2021january2022aretrospectivepopulationbasedmatchedcohortstudy
AT levybruhldaniel severehospitaleventsfollowingsymptomaticinfectionwithsarscov2omicronanddeltavariantsinfrancedecember2021january2022aretrospectivepopulationbasedmatchedcohortstudy
AT parentduchateletisabelle severehospitaleventsfollowingsymptomaticinfectionwithsarscov2omicronanddeltavariantsinfrancedecember2021january2022aretrospectivepopulationbasedmatchedcohortstudy